National Pension Service Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• The National Pension Service increased its stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 5.8%, holding approximately 0.22% of the company's stock valued at $395.19 million after purchasing additional shares.
• Insider trading activity included Gary S. Guthart selling over 7,800 shares for approximately $3.94 million, reducing his stake by 37.44%.
• Recent analyst reports show a consensus rating of "Moderate Buy" for Intuitive Surgical, with price targets ranging from $571.00 to $650.00.

National Pension Service lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 797,929 shares of the medical equipment provider's stock after buying an additional 43,408 shares during the quarter. National Pension Service owned approximately 0.22% of Intuitive Surgical worth $395,190,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Parvin Asset Management LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $26,000. Chilton Capital Management LLC lifted its stake in Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares during the period. Global Financial Private Client LLC lifted its stake in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. purchased a new stake in Intuitive Surgical in the first quarter worth $26,000. Finally, LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical in the first quarter worth $30,000. Institutional investors own 83.64% of the company's stock.

Insider Transactions at Intuitive Surgical

In other news, insider Gary S. Guthart sold 2,800 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the transaction, the insider owned 18,520 shares of the company's stock, valued at $9,171,844.80. This represents a 13.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,839 shares of company stock worth $7,896,972 in the last three months. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Up 0.7%

ISRG traded up $3.18 during mid-day trading on Friday, reaching $480.26. 1,436,064 shares of the company traded hands, compared to its average volume of 1,995,683. The stock has a market capitalization of $172.16 billion, a P/E ratio of 66.98, a P/E/G ratio of 5.06 and a beta of 1.59. The company's fifty day moving average price is $510.29 and its 200-day moving average price is $526.13. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's quarterly revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.78 EPS. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Royal Bank Of Canada lifted their price objective on Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research report on Wednesday, July 23rd. Truist Financial boosted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Barclays dropped their price target on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating and issued a $595.00 price target (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Finally, Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.